The prevention of Dirofilaria repens infection with ivermectin/pyrantel chewables.
This trial was conducted to test the efficacy of ivermectin/pyrantel chewables in preventing the development of Dirofilaria repens in dogs. The trial included 155 dogs from an endemic area in North-Western Italy. Prior to enrollment in the study, none of the dogs had microfilariae of D. immitis or D. repens in a concentration test, and all dogs were also seronegative for adult heartworm antigen. Animals remained with their owners and were dosed six times, at monthly intervals according to body weight. Efficacy against D. repens was evaluated approximately 6 and 12 months after the first dosing. None of the treated dogs was found to harbour microfilariae of D. repens or D. immitis on either occasion, whereas 6 of 24 untreated controls had circulating D. repens microfilariae at the final testing. The treatment was well accepted by all dogs.
Pollono
F
F
Merck Research Laboratories, Germany.
Pollmeier
M
M
Rossi
L
L
D000284:Administration, Oral; D000818:Animals; D004184:Dirofilariasis / Q000517:prevention & control*; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D005369:Filaricides / Q000008:administration & dosage / Q000627:therapeutic use*; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use*; D008409:Mastication; D011715:Pyrantel / Q000008:administration & dosage / Q000627:therapeutic use*
D005369:Filaricides; D011715:Pyrantel; D007559:Ivermectin